Transparency Market Research in its new report titled, “Chordoma Disease Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026, ” provides key insights on the chordoma disease market. The new report anticipates that the rise in prevalence of bone malignancy, increase in government activities for bone cancer awareness, and increase in the geriatric population will drive the chordoma disease market during the forecast period i. e, 2018-2026.
The TMR report has split the global chordoma disease market based on diagnosis, treatment, end-user, and region. In terms of diagnosis, the global market is segmented into blood tests, imaging, biopsy, and others. Among these, the imaging segment can be further categorized into magnetic resonance imaging (MRI), Xray, positron emission tomography (PET) scanning, computed tomography (CT) scan, and bone scan.
Based on treatment, the TMR report has bifurcated the global chordoma disease market into chemotherapy, cryosurgery, radiosurgery, targeted therapy, radiation therapy, surgical treatments, and others. The surgical treatments segment is further divided into radical resections, spinal chordoma, sacral chordoma, skull base chordoma, and others. The chemotherapy segment can be further sub-segmented into doxorubicin, methotrexate, and others. Additionally, the targeted therapy segment can be further categorized into bevacizumab, erlotinib, and others.
In terms of end-user, the TMR report has divided the global chordoma disease market into hospitals, clinics, cancer care centers, and others. The hospitals segment is predicted to be highly lucrative owing to the preference of treatment in hospitals. Based on regional perspective, the global chordoma disease market is categorized into Asia Pacific, North America, Western Europe, Eastern Europe, Latin America, and Middle East & Africa. Among these, North America and Europe accounted for a prominent share of the chordoma disease market, followed by Asia Pacific.
The U. S. dominated the chordoma disease market in North America, due to factors such as technological advancements, extensive R&D, and increasing healthcare awareness about the treatment and management of chordoma. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. New product launches, favorable regulations, and rise in awareness are likely to drive the market in Asia Pacific during the forecast period, as per the TMR report.
Major players operating in the global chordoma disease market are included in this report to give a better competitive analysis and these are AstraZeneca plc, Actavis plc, Celgene Corporation, F. Hoffmann-La Roche AG, Novartis International AG, Pfizer, Inc. , Bayer AG, Amgen, Inc. , Bristol-Myers Squibb and Company, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S. A, and others.
Request a free brochure report here- http://bit.ly/2NxyubI
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. We are leaders in analytics, research, and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a preeminent provider of cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who hold a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453